Categories: HospitalsNewsRobotics

LEM Surgical AG Secures CHF 22 Million in Series B Funding to Ready Robotic System for FDA Submission

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

BERN, SWITZERLAND / ACCESSWIRE / January 4, 2024 / LEM Surgical AG, an innovative surgical robotics company headquartered in Bern, Switzerland, announces the successful completion of its Series B funding, securing CHF 22 million. The round, which was strongly oversubscribed, reflects the strong investors’ confidence in LEM Surgical’s differentiated approach.

LEM Surgical Logo
Company Logo of LEM Surgical

This substantial funding boost is attributed to the enthusiastic participation of new investors from both the United States and Switzerland. The infusion of capital is strategically earmarked to propel the advancement of LEM Surgical’s product development initiatives and readiness for FDA submission in the second half of 2024. With this latest injection of capital, LEM Surgical is well-positioned to achieve its objectives and to further solidify its potential in the field of surgical robotics.

Yossi Bar, founder and CEO of LEM Surgical, expressed the company’s vision, stating, “Our goal is to revolutionize the experience for surgeons, clinical teams, and hospitals engaged in robotic surgery. We deeply appreciate the trust and support of our new investors. It underscores the unwavering confidence our investors have in the future success of our groundbreaking technology.”

About LEM Surgical AG

LEM Surgical is at the forefront of shaping the future through the creation of the next generation of robotic surgery platforms. The primary focus of its development efforts is centered around surpassing the capabilities of existing robotic platforms for spine surgery.

The company was founded in 2021 by Prof. Dr. Stefan Weber (CEO, CAScination AG), Marco Matulic (CTO, CAScination AG), Simon Michel (CEO, Ypsomed Group), Prof. Dr. Andreas Raabe (Director, Department of Neurosurgery, Inselspital Bern) and Yossi Bar (previously Director R&D at Mazor Robotics Ltd).

Follow on LinkedIn www.linkedin.com/company/lem-surgical-ag/

www.lemsurgical.com

Contact Information

Yossi Bar
Chief Executive Officer
communications@lemsurgical.com

SOURCE: LEM Surgical AG

View the original press release on newswire.com.

Staff

Recent Posts

Semler Scientific® Appoints Joe Burnett as Director of Bitcoin Strategy; Targets Owning at Least 10,000 Bitcoins by Year-End 2025 and 105,000 by Year-End 2027

CAMPBELL, Calif., June 19, 2025 /PRNewswire/ -- Semler Scientific, Inc. (Nasdaq: SMLR), a publicly traded…

5 hours ago

The Department of Health – Abu Dhabi and Abbot Unite to Manufacture Pharmaceuticals Locally in Abu Dhabi

Reinforcing Abu Dhabi's position as a global life science hub ABU DHABI, UAE, June 19,…

5 hours ago

ACI Infotech Accelerates Growth with Exclusive Salesforce-Agentforce Partnership and Bold Vision for the Future

SOMERSET, N.J., June 19, 2025 /PRNewswire/ -- ACI Infotech, a tech consulting powerhouse with deep AI,…

6 hours ago

Bridge joins the Elation Health Partner Hub to Elevate Patient Engagement for Elation EHR Users

The award-winning BridgeInteract patient engagement platform gives Elation customers a turnkey suite of self-service tools…

6 hours ago